Plans to expand clinical program and uplist to the NASDAQ were also presented. NEW YORK, NY / ACCESS Newswire / May 21, 2026 / Cell Source, Inc. (OTC PINK:CLCS) ("Cell Source" or the "Company"), a leading innovator in immune tolerance management, recently presented its plans to expand its clinical program for haploidentical (partially mismatched donor) stem cell (e.g.









